Could a Sentinel Lymph Node Biopsy Be Performed with Isolated Methylene Blue Injection in a Patient with a History of Skin-Sparing Mastectomy and Prosthetic Reconstruction?

Year 2020, Volume: 1 Issue: 1, 34 - 37, 22.09.2020

Ümit Özdemir İhsan Burak Karakaya Ahmet Karayiğit Dursun Burak Özdemir Hayrettin Dizen

https://doi.org/10.47482/acmr.2020.6

Abstract

Evaluation of lymphatic spread in early stage breast cancer without clinical and radiological evidence of metastasis can be performed by sentinel lymph node biopsy (SLNB). However, controversies about performing the SLNB in patients who have a history of major breast or axillary region surgery keep going. This case report presents the outcomes of a SLNB performed on a 42-year-old woman who had been previously treated with bilateral nipple and skin-sparing mastectomy and breast reconstruction with areolar complex transfer and silicone breast implants. 0.5% diluted methylene blue solution was injected intradermally as a marker. SLNB is an inexpensive and effective method for adequate axillary evaluation in cases with previous mastectomy history. Intradermal injection of 0.5% diluted methylene blue could reduce the risk of skin necrosis and breast prosthesis rupture.

Keywords

Sentinel Lymph Node Biopsy, Breast Cancer, Methylene Blue, Previous Skin-Sparing Mastectomy.

References

• 1.Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early- Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(5):561-4.
• 2. Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. Jama. 2013;310(13):1385-94.
• 3. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. Journal of Clinical Oncology. 2000;18(13):2560-6.
• 4. Celebioglu F, Frisell J, Danielsson R, Bergkvist L. Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2007;33(3):276-80.
• 5. Ahmed M, Baker R, Rubio IT. Meta-analysis of aberrant lymphatic drainage in recurrent breast cancer. The British journal of surgery. 2016;103(12):1579-88.
• 6. Poodt IGM, Vugts G, Schipper RJ, Roumen RMH, Rutten HJT, Maaskant-Braat AJG, et al. Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. The British journal of surgery. 2019;106(5):574-85.
• 7. Karanlik H, Ozgur I, Kilic B, Fathalizadeh A, Sanli Y, Onder S, et al. Sentinel lymph node biopsy and aberrant lymphatic drainage in recurrent breast cancer: Findings likely to change treatment decisions. Journal of surgical oncology. 2016;114(7):796-802.
• 8. Munhoz AM, Aldrighi C, Buschpiegel C, Ono C, Montag E, Fells K, et al. The feasibility of sentinel lymph node detection in patients with previous transaxillary implant breast augmentation: preliminary results. Aesthetic plastic surgery. 2005;29(3):163-8.
• 9. Gray RJ, Forstner-Barthell AW, Pockaj BA, Schild SE, Halyard MY. Breast-conserving therapy and sentinel lymph node biopsy are feasible in cancer patients with previous implant breast augmentation. The American journal of surgery. 2004;188(2):122-5.
• 10. Mottura AA, Del Castillo R. Transaxillary Breast Augmentation: Two Breast Cancer Patients with Successful Sentinel Lymph Node Diagnosis. Aesthetic Plastic Surgery. 2007;31(5):544-9.
• 11. Karam A, Stempel M, Cody III HS, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy. Journal of the American College of Surgeons. 2008;207(4):543-8.
• 12. Intra M, Veronesi P, Gentilini OD, Trifirò G, Berrettini A, Cecilio R, et al. Sentinel lymph node biopsy is feasible even after total mastectomy. Journal of surgical oncology. 2007;95(2):175-9.
• 13. Vicente DA, Henry LR, Hahm G, Soballe PW, Smart D. Axillary sentinel lymph node biopsy after mastectomy: a case report. World Journal of Surgical Oncology. 2010;8(1):59.
• 14. Bleicher RJ, Kloth DD, Robinson D, Axelrod P. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy. Journal of surgical oncology. 2009;99(6):356-60.